The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 16, 2021

Filed:

Mar. 01, 2018
Applicant:

IL Dong Pharmaceutical Co., Ltd., Seoul, KR;

Inventors:

Hyuk-Sang Kwon, Seoul, KR;

Jong-Hee Ko, Gyeonggi-do, KR;

Young-Min Lee, Incheon, KR;

Hyei-Yoon Jung, Seoul, KR;

Seok-Woo Yang, Gyeonggi-do, KR;

Jae-Hoon Kang, Seoul, KR;

Yong-Sung Kim, Gyeonggi-do, KR;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/16 (2006.01); C07K 16/22 (2006.01); C07K 19/00 (2006.01); C07K 14/49 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 38/10 (2006.01); A61P 35/04 (2006.01); A61P 35/00 (2006.01); A61K 38/18 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/49 (2013.01); A61K 38/10 (2013.01); A61K 38/16 (2013.01); A61K 38/17 (2013.01); A61K 38/1866 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 16/22 (2013.01); C07K 19/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2319/30 (2013.01);
Abstract

The present invention relates to a pharmaceutical composition containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial cell growth factor (anti-VEGF) agent are fused, for treating cancer or angiogenesis-related diseases. More specifically, the present invention relates to a use of the fusion protein for treating cancer or angiogenesis-related diseases, wherein the fusion protein improves the tissue penetrability of an anti-vascular endothelial cell growth factor agent and exerts a cancer targeting effect, thereby producing an excellent angiogenesis inhibiting effect and exhibiting a therapeutic effect on cancer showing resistance or unresponsiveness to the anti-VEGF agent.


Find Patent Forward Citations

Loading…